71P Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: A pooled ctDNA analysis of three clinical trials

Annals of Oncology 2026 Open access

Read full text
Authors: V. Martelli, J. Vidal Barrull, P. Ciracì, P. Berenguer-Molins, A. Sibilio, C. Fernández Rodríguez, B. Bellosillo Paricio, J.L. Linares, V. Conca, C. Ugolini, P. Vignali, M.B. Landi
+8 more G. Martini, S. Napolitano, F. De Vita, R. Bordonaro, F. Ciardiello, D. Ciardiello, C. Cremolini, C. Montagut
DOI: 10.1016/j.annonc.2026.05.072
Cited by: 1

Fields of Study & Subjects

Cancer Genomics and Diagnostics Colorectal Cancer Treatments and Studies PARP inhibition in cancer therapy

Publication details

Journal / source
Annals of Oncology
Publisher
Elsevier BV
Volume
37
Pages
S26–S27
Publication date
1 July 2026
Language
EN